Abstract
Sepsis is defined as life-threatening organ dysfunction caused by a dysregulated host response to infection. Studies have indicated that immune dysfunction plays a central role in the pathogenesis of sepsis. Dendritic cells (DCs) play a crucial role in the emergence of immune dysfunction in sepsis. The major manifestations of DCs in the septic state are abnormal functions and depletion in numbers, which are linked to higher mortality and vulnerability to secondary infections in sepsis. Apoptosis is the most widely studied pathway of number reduction in DCs. In the past few years, there has been a surge in studies focusing on regulated cell death (RCD). This emerging field encompasses various forms of cell death, such as necroptosis, pyroptosis, ferroptosis, and autophagy-dependent cell death (ADCD). Regulation of DC’s RCD can serve as a possible therapeutic focus for the treatment of sepsis. Throughout time, numerous tactics have been devised and effectively implemented to improve abnormal immune response during sepsis progression, including modifying the functions of DCs and inhibiting DC cell death. In this review, we provide an overview of the functional impairment and RCD of DCs in septic states. Also, we highlight recent advances in targeting DCs to regulate host immune response following septic challenge.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Medical Innovation Research Division of the Chinese PLA General Hospital, Translational Medicine Research Center, Beijing, China (GRID:grid.414252.4) (ISNI:0000 0004 1761 8894)
2 Southern Medical University, Department of Critical Care Medicine, Affiliated Chenzhou Hospital (the First People’s Hospital of Chenzhou), Chenzhou, China (GRID:grid.284723.8) (ISNI:0000 0000 8877 7471)
3 The First Medical Center of Chinese PLA General Hospital, Department of General Surgery, Beijing, China (GRID:grid.414252.4) (ISNI:0000 0004 1761 8894)
4 Medical Innovation Research Division of the Chinese PLA General Hospital, Translational Medicine Research Center, Beijing, China (GRID:grid.414252.4) (ISNI:0000 0004 1761 8894); The First Medical Center of Chinese PLA General Hospital, Department of General Surgery, Beijing, China (GRID:grid.414252.4) (ISNI:0000 0004 1761 8894)





